Magenta therapeutics and bluebird bio announce a phase 2 clinical trial collaboration to evaluate magenta's mgta-145 for mobilizing and collecting stem cells in adults and adolescents with sickle cell disease

Cambridge, mass.--(business wire)--magenta therapeutics (nasdaq: mgta) and bluebird bio, inc. (nasdaq: blue) today announced an exclusive clinical trial collaboration to evaluate the utility of mgta-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (scd). the data from this clinical trial could provide proof-of-concept for mgta-145, in combination with plerixafor, as the preferred mobilization regimen for patien
DNTH Ratings Summary
DNTH Quant Ranking